Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.53 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.53 |
| ▸ | LTB4R | Q15722 | 8/20 | 0.50 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.49 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL9875660 | 0.98 | MAPT (0.60) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| Bromide SCHEMBL9732524 | 0.94 | HDAC3 (0.61) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| Bromide SCHEMBL2131203 | 0.84 | MAPT (0.66) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| Bromide SCHEMBL8658831 | 0.83 | ALOX5 (0.50) | MAPTRXFP1MAPK1TBXAS1 | |
| SCHEMBL7617985 | 0.83 | MAPT (0.68) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL1197247 | 0.82 | MAPT (0.78) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| Heptane SCHEMBL11228269 | 0.80 | MAPT (0.59) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| Bromide SCHEMBL9650134 | 0.80 | HDAC1 (0.67) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| Bromide SCHEMBL9762632 | 0.80 | LTA4H (0.42) | HDAC3MAPK1ADRA1AHDAC4SLC6A3 | |
| SCHEMBL1008757 | 0.79 | MAPT (1.00) | MAPTRXFP1HDAC3MAPK1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205362-A1 | LIPID NANOPARTICLES | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2025-06-26 | — | — | US | disclosed |
| EP-4501359-A1 | LIPID NANOPARTICLES | National University Corporation Hokkaido University (JP) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023188830-A1 | LIPID NANOPARTICLES | 国立大学法人北海道大学 | 2023-10-05 | — | — | WO | disclosed |
| US-20140357569-A1 | CYCLOSPORIN CONJUGATES | UCL BUSINESS PLC (GB) | 2014-12-04 | — | — | US | disclosed |
| US-20120157385-A1 | CYCLOSPORIN CONJUGATES | UCL BUSINESS PLC (GB) | 2012-06-21 | — | — | US | disclosed |
| EP-2453925-A2 | CYCLOSPORIN CONJUGATES | UCL Business PLC (GB) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011010084-A2 | CYCLOSPORIN CONJUGATES | UCL BUSINES PLC (GB) | 2011-01-27 | — | — | WO | disclosed |
| EP-0150892-B1 | SUBSTITUTED ALKYLIDENE IMIDAZOLES | G.D. Searle & Co. (US) | 1991-04-24 | — | — | EP | disclosed |
| US-4837333-A | SELECTIVE INHIBITOR OF THROMBOXANE SYNTHETASE ENZYME | G. D. SEARLE & CO. (US) | 1989-06-06 | — | — | US | disclosed |
| EP-0150892-A2 | Substituted alkylidene imidazoles | G.D. Searle & Co. (US) | 1985-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250205362-A1 | LIPID NANOPARTICLES | ECH1, C1R, SGMS1 | ADRA1A 379/4885SLC6A3 3766/4885MAPT 3784/4885 |
| US-20120157385-A1 | CYCLOSPORIN CONJUGATES | CYP11B1, SHMT2, MRM1 | ADRA1A 2232/4885SLC6A3 1919/4885MAPT 3064/4885 |
| US-20140357569-A1 | CYCLOSPORIN CONJUGATES | CYP11B1, SHMT2, MRM1 | ADRA1A 2158/4885SLC6A3 1919/4885MAPT 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.